2007
DOI: 10.1016/j.ymgme.2006.10.005
|View full text |Cite
|
Sign up to set email alerts
|

Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

8
92
0

Year Published

2009
2009
2015
2015

Publication Types

Select...
7
2

Relationship

2
7

Authors

Journals

citations
Cited by 83 publications
(100 citation statements)
references
References 41 publications
8
92
0
Order By: Relevance
“…The progression of vacuolar changes quantified in our fucosidosis study have not been systematically described in other LSD models, so information on the rate of progression in different regions of the CNS is not available for comparison. However, a recent study of MPS IIIA mice reported the rate of progression of vacuolation in CNS from birth to 20 weeks using a qualitative method of assessment [24] .…”
Section: Discussionmentioning
confidence: 99%
“…The progression of vacuolar changes quantified in our fucosidosis study have not been systematically described in other LSD models, so information on the rate of progression in different regions of the CNS is not available for comparison. However, a recent study of MPS IIIA mice reported the rate of progression of vacuolation in CNS from birth to 20 weeks using a qualitative method of assessment [24] .…”
Section: Discussionmentioning
confidence: 99%
“…For adult-injected mice, 6-week-old MPS-IIIA and unaffected mice received bilateral injections into the brain parenchyma (Savas et al, 2004) or cerebrospinal fluid (Hemsley et al, 2007) using established methods.…”
Section: Intracranial Injections Tissue Collection and Antibody Titementioning
confidence: 99%
“…While intra-cerebrospinal fluid delivery of recombinant human SGSH (rhSGSH) is an effective means of restoring enzyme activity and ameliorating pathological and clinical symptoms in MPS-IIIA mice (Hemsley et al, 2007(Hemsley et al, , 2009, alternate strategies that allow life-long treatment from a single intervention would be of considerable value. Gene transfer vectors derived from common human pathogens may show limited longevity and efficacy in patients due to the high frequency of memory immunity against these vectors (Chirmule et al, 1999).…”
Section: Introductionmentioning
confidence: 99%
“…MPS-I dogs treated intrathecally with recombinant human iduronidase developed serum and CSF antibodies against the enzyme, as well as meningitis (15,16). Similarly, intrathecally treated MPS-IIIA dogs developed antibodies against recombinant human sulfamidase, as well as meningitis (23), whereas MPS-IIIA mice treated with repeated IT-INJs of the same enzyme developed circulating antibodies without meningitis or adverse reactions (24)(25)(26). The small, focal, Wallerian-type degeneration observed near the site of IT-INJ in most intrathecally treated cats, irrespective of presence or absence of polysorbate-80, was attributed to mild iatrogenic trauma produced during IT-INJ, as previously reported (14), again highlighting the importance of a good injection technique (14).…”
Section: Articlesmentioning
confidence: 99%